Sangamo Therapeutics, Inc., incorporated in Delaware on June 22, 1995, focuses on the development and commercialization of novel transcription factors for gene regulation and gene modification. The company is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of DNA-binding proteins for new therapeutic strategies for unmet medical needs. Currently, the company's scientific and business development efforts focus on gene regulation and modification of new zinc finger DNA-binding protein engineering. The company's strategy is to develop highly specific zinc finger protein nucleases and zinc finger protein transcription factors through early-stage clinical trials and strategic partnerships with biopharmaceutical companies to perform late-stage clinical trials and commercial development.